ASTH's stock plummeted 22% following CMS's proposed Medicare payment updates for 2027, indicating minimal growth for Medicare Advantage. The company's reliance on Medicare shines a spotlight on its revenue structure, but some analysts view the current price drop as a potential buying opportunity given long-term growth prospects in delegated care agreements.
Truist Securities upgraded Astrana Health Inc ASTH. Astrana serves over 10,000 providers and 1.0 million patients. Lower trends compared to peers indicate potential pent-up demand captured by Astrana's care model. Truist sees underappreciated tailwinds for Astrana, including presence in Southern California and low RAF score advantage. Astrana Health projected revenue growth of 25%-30% in the next few years.